68 results found.
      
Anika Therapeutics Posts 1Q17 Orthobiologic Revenue
Anika Therapeutics posted 1Q17 orthobiologic revenue of US $20.2MM, +3.3% vs. 1Q16. 
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
Anika Therapeutics 4Q16 and 2016 Revenue
Anika Therapeutics posted 2016 orthobiologic revenue of US $89.7MM, +22.5% vs. 2015, with 4Q16 revenue of $24.4M...
Company Revenue 3Q16: A Final Look
By Julie A. Vetalice As we wrap up orthopaedic revenue for the latest reporting period, we observe that Stryker and Zimmer Biomet lead the largest orthopaedic companies in 3Q16 growth:
Anika Therapeutics Reports 3Q16 Orthobiologic Revenue
Anika Therapeutics posted 3Q16 orthobiologic revenue of US $22.4MM, +9.6% vs. 3Q15.
Company Revenue Update, 1H16
By Julie A. Vetalice We complete our coverage of 1H16 revenue in this issue. Stryker and Smith & Nephew lead the top five in growth, with 1H16 performance in the low-single-digits compared to 1H15. DePuy Synthes and Zimmer Biomet reported
Anika Therapeutics Posts 2Q16 Orthobiologic Revenue
Anika Therapeutics posted 2Q16 orthobiologic revenue of US $23.3MM, +20.9% vs. 2Q15, as-reported.
Anika Therapeutics Posts 1Q16 Revenue
Anika Therapeutics posted 1Q16 orthobiologic revenue of US $19.6MM, +63.5% vs. 1Q15, as-reported.
Sanofi Reports 1Q16 Synvisc Revenue
Sanofi posted 1Q16 Synvisc viscosupplementation product revenue of €88.0MM (~US $100.7MM), +3.5% from 1Q15, as-reported...
Anika Therapeutics Posts 4Q15/2015 Revenue
Anika Therapeutics posted 4Q15 orthobiologics revenue of US $21.5MM, +63% vs. 4Q14, and 2015 revenue of $73.2M...
Company Revenue 2015: Anika Therapeutics
2015: $73.2MM, +18% 4Q15: $21.5MM, +63% Received $5MM milestone revenue for reaching target MONOVISC U.S. end-user sales of $50MM Full-year combined U.S. viscosupplementation revenue +24%, with MONOVISC more than tripling Commenced 200-patient enr...
Anika Therapeutics 3Q15 Orthopaedic Revenue
Anika Therapeutics posted 3Q15 orthobiologics revenue of US $20.4MM, +7.9% vs. 3Q14, and YTD 2015 revenue of ...
BARE BONES® - July 29, 2015
Anika Therapeutics reported 2Q15 orthobiologic sales of US $19.2MM, +5.5% from 2Q14. (Anika Th...
BARE BONES® - April 28, 2015
Anika Therapeutics reported 1Q15 orthobiologics sales of US $11.9MM, +3.4% from 1Q14. (
BARE BONES® - February 25, 2015
Anika Therapeutics reported 4Q14 orthobiologics revenue of US $13.2MM, -13.8% from 4Q13, and 2014 revenue of $61.9MM, +10.7% from 2013. (
2014 Revenue: Anika Therapeutics
4Q14 revenue: $13.2MM, -14% 2014 revenue: $61.9MM, +11% (MONOVISC +258%)   4Q revenues impacted by lack of unique CMS J-Code for MONOVISC for 8 months post-launch, DePuy Mitek inventory reset, temporary slowdown in ex-U.S. sales...
BARE BONES® - October 29, 2014
Anika Therapeutics reported 3Q14 orthobiologics sales of US $18.9MM, +47% from 3Q13. (
3Q14 Revenue: Anika Therapeutics
Orthobiologics sales $18.9MM, +47% ORTHOVISC sales from Mitek +15% Ex-U.S. MONOVISC +40%   Notes weak European economies and slower than planned expansion in EMEA markets impacting ORTHOVISC sales Maj...
BARE BONES® - July 30, 2014
Anika Therapeutics reported 2Q14 orthobiologic sales of US $18.2MM, +11% from 2Q13. (
2Q14 Revenue: Anika Therapeutics
Orthobiologic sales $18.2MM, +11% (ex-U.S. MONOVISC +27%) Received $5MM milestone payment associated with U.S. MONOVISC license agreement Majority of U.S. sales reflect physician/patient conversion from competing single-injection products to MONOVISC
1Q14 Revenue: Anika Therapeutics
$11.5MM, +3% (MONOVISC ~$1.7MM) Marked 1st commercial sale of MONOVISC in U.S., not yet seeing cannibalization of ORTHOVISC Seeks to complete clinical trial and submit CE Mark application by end of 2014 for Cingal HA+ steroid injection Planning...
BARE BONES® - April 29, 2014
Anika Therapeutics reported 1Q14 orthobiologics sales of US $11.5MM, +3% from 1Q13. (Anika Therapeutics, Inc., 4/29/14)
4Q13/2013 Revenue: Anika Therapeutics
4Q13 revenue: $15.3MM, -22% 2013 revenue: $55.9MM, +12% U.S. ORTHOVISC +21% (Mitek revenue +9%) Ex-U.S. viscosupplementation +34% (ORTHOVISC +30%, MONOVISC +50%)   Growth fueled primarily by...
BARE BONES® - February 26, 2014
Anika Therapeutics reported 4Q13 orthobiologics revenue of US $15.3MM, -22% from 4Q12, and 2013 revenue of $55.9MM, +12% from 2012. (
BARE BONES® - October 30, 2013
Anika Therapeutics reported 3Q13 orthobiologics sales of US $12.8MM, +39% from 3Q12. (Anika Therapeutics, Inc., 10/30/...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group